FR2844521B1 - MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS - Google Patents

MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS

Info

Publication number
FR2844521B1
FR2844521B1 FR0211416A FR0211416A FR2844521B1 FR 2844521 B1 FR2844521 B1 FR 2844521B1 FR 0211416 A FR0211416 A FR 0211416A FR 0211416 A FR0211416 A FR 0211416A FR 2844521 B1 FR2844521 B1 FR 2844521B1
Authority
FR
France
Prior art keywords
cytokines
marker
activation
measurement
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0211416A
Other languages
French (fr)
Other versions
FR2844521A1 (en
Inventor
Romeuf Christophe De
Christine Gaucher
Arnaud Glacet
Frederic Dhainaut
Dominique Bourel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR0211416A priority Critical patent/FR2844521B1/en
Priority to FR0307067A priority patent/FR2844513B1/en
Priority to FR0307066A priority patent/FR2844455B1/en
Priority to EP03773779A priority patent/EP1537147B9/en
Priority to PCT/FR2003/002714 priority patent/WO2004028564A2/en
Priority to AU2003282160A priority patent/AU2003282160A1/en
Priority to PCT/FR2003/002713 priority patent/WO2004029092A2/en
Priority to CA2498383A priority patent/CA2498383C/en
Priority to EP15182965.2A priority patent/EP3001198A1/en
Priority to US10/527,664 priority patent/US20060127392A1/en
Priority to CA002498787A priority patent/CA2498787A1/en
Priority to PCT/FR2003/002715 priority patent/WO2004024768A2/en
Priority to US10/527,665 priority patent/US7595165B2/en
Priority to JP2004535611A priority patent/JP4368800B2/en
Priority to AU2003283469A priority patent/AU2003283469C1/en
Priority to JP2004539110A priority patent/JP2006504700A/en
Priority to CA2498315A priority patent/CA2498315C/en
Priority to DK03773780.6T priority patent/DK1537419T3/en
Priority to AT03773779T priority patent/ATE486094T1/en
Priority to EP03775438A priority patent/EP1545614A2/en
Priority to AU2003282161A priority patent/AU2003282161B2/en
Priority to DE60334700T priority patent/DE60334700D1/en
Priority to JP2004539109A priority patent/JP2006516951A/en
Priority to US10/527,666 priority patent/US20050271652A1/en
Priority to EP03773780A priority patent/EP1537419B1/en
Priority to EP09152731A priority patent/EP2092939A3/en
Priority to AT03773780T priority patent/ATE511654T1/en
Publication of FR2844521A1 publication Critical patent/FR2844521A1/en
Application granted granted Critical
Publication of FR2844521B1 publication Critical patent/FR2844521B1/en
Priority to IL167385A priority patent/IL167385A/en
Priority to IL167381A priority patent/IL167381A/en
Priority to US12/234,609 priority patent/US20090081216A1/en
Priority to JP2009190989A priority patent/JP5951923B2/en
Priority to US12/585,900 priority patent/US20100323368A1/en
Priority to US12/576,202 priority patent/US20100145026A1/en
Priority to IL230101A priority patent/IL230101A/en
Priority to JP2013272030A priority patent/JP6238743B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0211416A 2002-09-13 2002-09-13 MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS Expired - Lifetime FR2844521B1 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR0211416A FR2844521B1 (en) 2002-09-13 2002-09-13 MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS
FR0307066A FR2844455B1 (en) 2002-09-13 2003-06-12 TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
FR0307067A FR2844513B1 (en) 2002-09-13 2003-06-12 ANTIBODIES FOR ADCC AND INDUCING PRODUCTION OF CYTOKINS.
AT03773779T ATE486094T1 (en) 2002-09-13 2003-09-15 ADCC-MEDIATING ANTIBODIES AGAINST HLA-DR THAT INDUCE THE PRODUCTION OF CYTOKINES
AU2003282160A AU2003282160A1 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
DE60334700T DE60334700D1 (en) 2002-09-13 2003-09-15 ADCC-RELATED ANTIBODIES TO HLA-DR INDUCING THE PRODUCTION OF CYTOKINS
CA2498383A CA2498383C (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
EP15182965.2A EP3001198A1 (en) 2002-09-13 2003-09-15 Treatment of conditions escaping the immune response by optimised antibodies
US10/527,664 US20060127392A1 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
CA002498787A CA2498787A1 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
PCT/FR2003/002715 WO2004024768A2 (en) 2002-09-13 2003-09-15 Cytokine production-inducing antibody
US10/527,665 US7595165B2 (en) 2002-09-13 2003-09-15 Method of measuring activation of effector cells
JP2004535611A JP4368800B2 (en) 2002-09-13 2003-09-15 Cytokine production-inducing antibody
AU2003283469A AU2003283469C1 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
JP2004539110A JP2006504700A (en) 2002-09-13 2003-09-15 Treatment of pathological conditions that escape immune responses using optimized antibodies
CA2498315A CA2498315C (en) 2002-09-13 2003-09-15 Cytokine production-inducing antibody
DK03773780.6T DK1537419T3 (en) 2002-09-13 2003-09-15 Test for CD16-mediated ADCC efficacy of monoclonal and polyclonal antibodies
PCT/FR2003/002714 WO2004028564A2 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
EP03773779A EP1537147B9 (en) 2002-09-13 2003-09-15 Antibody anti hla-dr with an increased adcc and inducing cytokine production
AU2003282161A AU2003282161B2 (en) 2002-09-13 2003-09-15 Cytokine production-inducing antibody
PCT/FR2003/002713 WO2004029092A2 (en) 2002-09-13 2003-09-15 Antibody for adcc and inducing cytokine production
JP2004539109A JP2006516951A (en) 2002-09-13 2003-09-15 Antibodies for induction of ADCC and cytokine production
EP03773780A EP1537419B1 (en) 2002-09-13 2003-09-15 Test for CD16-mediated ADCC efficacy of monoclonal or polyclonal antibodies
US10/527,666 US20050271652A1 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
EP09152731A EP2092939A3 (en) 2002-09-13 2003-09-15 Therapeutical use of antibody inducing the production of cytokines
AT03773780T ATE511654T1 (en) 2002-09-13 2003-09-15 TEST FOR CD16-MEDIATED ADCC EFFECTIVENESS OF MONOCLONAL OR POCLONAL ANTIBODIES
EP03775438A EP1545614A2 (en) 2002-09-13 2003-09-15 Treatment of pathologies which escape the immune response, using optimised antibodies
IL167385A IL167385A (en) 2002-09-13 2005-03-10 Method for selecting a monoclonal antibody for increased antibody-dependent cellular cytotoxicity activity
IL167381A IL167381A (en) 2002-09-13 2005-03-10 Use of an optimized monoclonal antibody for preparing a medicinal product for the treatment of pathologies which escape the immune response
US12/234,609 US20090081216A1 (en) 2002-09-13 2008-09-19 Treatment of pathologies which escape the immune response, using optimized antibodies
JP2009190989A JP5951923B2 (en) 2002-09-13 2009-08-20 Treatment of pathological conditions that escape immune responses using optimized antibodies
US12/585,900 US20100323368A1 (en) 2002-09-13 2009-09-28 Cytokine production-inducing antibody
US12/576,202 US20100145026A1 (en) 2002-09-13 2009-10-08 Antibody for ADCC And Inducing Cytokine Production
IL230101A IL230101A (en) 2002-09-13 2013-12-23 Use of optimized antibodies for preparing medicaments for treatment of pathologies which escape the immune response
JP2013272030A JP6238743B2 (en) 2002-09-13 2013-12-27 Treatment of pathological conditions that escape immune responses using optimized antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0211416A FR2844521B1 (en) 2002-09-13 2002-09-13 MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS

Publications (2)

Publication Number Publication Date
FR2844521A1 FR2844521A1 (en) 2004-03-19
FR2844521B1 true FR2844521B1 (en) 2004-12-24

Family

ID=31897391

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0211416A Expired - Lifetime FR2844521B1 (en) 2002-09-13 2002-09-13 MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS

Country Status (1)

Country Link
FR (1) FR2844521B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894983B1 (en) * 2005-12-16 2012-08-17 Lab Francais Du Fractionnement ANTIBODY CHARACTERIZATION TEST.
EP1933137A1 (en) * 2006-12-15 2008-06-18 Glycode Method of investigating the response to a treatment using a monoclonal antibody
EP2062047B1 (en) * 2006-09-13 2011-03-09 Glycode Method for investigating the response to a treatment with a monoclonal antibody
FR2980271B1 (en) 2011-09-16 2013-10-11 Cisbio Bioassays METHOD FOR DETERMINING GLYCOSYLATION OF ANTIBODY
FR2988174B1 (en) 2012-03-19 2014-04-25 Cisbio Bioassays METHOD FOR DETERMINING THE CAPACITY OF ANTIBODY TO MAINTAIN CELLS CLOSE TO EACH OTHER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (en) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
AU2001267922A1 (en) * 2000-07-04 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Method of assaying the function of fc fragment of antibody

Also Published As

Publication number Publication date
FR2844521A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
DE60224687D1 (en) PROTECTIVE MEMBRANE FOR THE RECONFIGURATION OF A WORKPIECE
AU2003227360A1 (en) Novel amide derivatives or salts thereof
DE69911617D1 (en) STEREOLITHOGRAPHIC COMPOSITIONS FOR THE PRODUCTION OF POLYETHYLENE-LIKE OBJECTS
ITTO20030629A1 (en) PROCEDURE FOR THE CREATION OF LINKS AD
IT1298535B1 (en) PROCEDURE FOR THE PRODUCTION OF RANGE-BUTYROLACTONE
ITMI20031517A1 (en) PROCEDURE FOR ADJUSTING THE SPEED OF A VEHICLE
DE60018173D1 (en) GIESSFORM FOR THE PRODUCTION OF A COOLING ELEMENT
FR2844521B1 (en) MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS
FR2838170B1 (en) CLUTCH ACTUATORS
IT1298096B1 (en) PROCEDURE FOR THE PRODUCTION OF RANGE-BUTYROLACTONE
AU2003290028A8 (en) Multi-axis lens, beam system making use of the compound lens, and method of manufacturing the compound lens
FI20020593A (en) Process for the preparation of conjugated linoleic acid
ITMI20020933A0 (en) PROCEDURE FOR THE SYNTHESIS OF CLOPIDOGREL
PT1212321E (en) INTERMEDIARIES FOR THE PRODUCTION OF NAFTHYRIDINE-3-CARBOXYLIC ACID DERIVATIVES
AU2003288237A1 (en) Artificial esterases
AU2003240618A1 (en) Method for the production of a three-dimensional flat tissue transplant
NO20023199D0 (en) point Mater
DE59900891D1 (en) Tool for the production of structured sheets
AU2002304819A1 (en) Novel form of the phgpx protein as a diagnostic marker for male infertility
PT1511741E (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
ITMI20010964A0 (en) PROCEDURE FOR OBTAINING USEFUL COMPOUNDS FOR THE PRODUCTION OF CEFOTETAN AND NEW COMPOUNDS SO OBTAINED
AU2003241288A1 (en) Production of stable collagens
ITTO20020997A1 (en) SELF-ALIGNED PROCEDURE FOR THE MANUFACTURE OF
ITRM20030091A1 (en) PROCEDURE FOR THE PRODUCTION OF A MOISTURE-TIGHT CONNECTION.
AU2003246642A1 (en) Method for the production of a tower

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130903

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16